Chlorambucil

證據等級: L5

預測適應症: 8 個

Chlorambucil: From Chronic Lymphocytic Leukemia to CLL/SLL with IGHV Somatic Hypermutation

One-Sentence Summary

Chlorambucil is a well-established alkylating agent with a long history of use as frontline therapy for chronic lymphocytic leukemia (CLL) and related B-cell lymphoid malignancies. The TxGNN model predicts it may be effective for CLL/SLL with immunoglobulin heavy-chain variable-region gene (IGHV) somatic hypermutation — a molecularly defined, favorable-prognosis subtype — with the current targeted evidence search returning 0 clinical trials and 0 publications specifically addressing this molecular subtype.

Quick Overview

Item	Content
Original Indication	Not available in Malaysian regulatory record (license details not captured at time of extraction)
Predicted New Indication	CLL/SLL with IGHV somatic hypermutation
TxGNN Prediction Score	99.72%
Evidence Level	L5 (no subtype-specific studies retrieved)
Malaysia Market Status	✓ Marketed
Number of Registrations	1
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data was not available from DrugBank at the time of this report. Based on known pharmacology, chlorambucil is a nitrogen mustard–derived alkylating agent. It forms covalent cross-links between and within DNA strands, effectively halting DNA replication and transcription. This cytotoxic mechanism is particularly effective against proliferating lymphocytes, which explains the drug’s decades-long use as a first-line therapy in B-cell lymphoid malignancies including CLL.

CLL/SLL is biologically stratified into two major subtypes based on the mutational status of the immunoglobulin heavy-chain variable region (IGHV) gene. Tumour cells carrying IGHV somatic hypermutation — the predicted indication here — are derived from post-germinal centre B cells and typically show a more indolent disease course and better response to conventional chemoimmunotherapy. Chlorambucil-based regimens (e.g., chlorambucil + obinutuzumab, chlorambucil + rituximab) have been validated in Phase 3 trials enrolling CLL patients broadly, with meaningful response rates observed across IGHV-mutated cohorts in subgroup analyses.

The TxGNN prediction therefore reflects a mechanistically coherent and clinically plausible scenario. Chlorambucil’s well-characterised B-cell cytotoxicity aligns with the biology of IGHV-mutated CLL, which remains sensitive to DNA-damaging agents. The high TxGNN score (99.72%) likely reflects strong pathway connectivity between chlorambucil’s known targets and the molecular drivers of this CLL subtype in the knowledge graph. However, no dedicated prospective studies specifically enrolling IGHV-mutated CLL as a distinct stratum were retrieved in this evidence pack, which limits formal evidence grading.

Clinical Trial Evidence

Currently no related clinical trials registered for CLL/SLL with IGHV somatic hypermutation specifically.

Contextual note: Three completed Phase 3 trials involving chlorambucil in CLL broadly were identified in a parallel search query within this evidence pack. These include a randomised study of lenalidomide versus chlorambucil as first-line therapy in elderly B-CLL patients (NCT00910910; n=450), a safety evaluation of obinutuzumab with or without chemotherapy in previously untreated or relapsed/refractory CLL (NCT01905943; n=979), and a head-to-head comparison of alemtuzumab versus chlorambucil as frontline therapy in progressive B-CLL (NCT00046683; n=284). While none of these prospectively stratified by IGHV status as a primary endpoint, they establish a substantial Phase 3 evidence base for chlorambucil in CLL overall and may contain subgroup data relevant to IGHV-mutated disease.

Literature Evidence

Currently no related literature available for CLL/SLL with IGHV somatic hypermutation specifically.

Contextual note: One publication retrieved under the closely related rank-2 prediction (pregerminal centre CLL/SLL) describes the discovery of two distinct CLL subtypes — the IGHV-unmutated pre-germinal centre type and the IGHV-mutated post-germinal centre type — and discusses risk-adapted treatment approaches (PMID 12577769, Ned Tijdschr Geneeskd, 2003). This paper directly contextualises the biological basis of the rank-1 prediction.

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
—	—	—	—

The Malaysian regulatory record confirms 1 active registration for chlorambucil (market status: marketed). However, detailed product information — including the MAL authorization number, product name, dosage form, and approved indication text — was not captured in the data extracted at the time of this report. These details can be retrieved directly from the NPRA product search portal.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (Alkylating agent — Nitrogen mustard class)
Myelosuppression Risk	High — dose-dependent bone marrow suppression; neutropenia, thrombocytopenia, and anaemia are common and may be cumulative with repeated cycles
Emetogenicity Classification	Low to moderate
Monitoring Items	Full blood count (CBC with differential) before each cycle and at nadir; liver function tests; renal function; monitoring for secondary malignancy with long-term use
Handling Protection	Must comply with cytotoxic drug handling regulations; oral tablet/capsule formulation requires caregiver education on safe handling, storage, and disposal

Safety Considerations

Please refer to the package insert for safety information.

The safety data fields (key warnings, contraindications, and drug–drug interactions) were all identified as data gaps in this evidence pack. The NPRA-approved product monograph should be obtained and reviewed before any clinical or formulary decision is made. Known class-level concerns for alkylating agents include myelosuppression, secondary leukaemia risk with prolonged use, teratogenicity, and carcinogenicity.

Conclusion and Next Steps

Decision: Hold

Rationale: No clinical trials or publications specifically addressing chlorambucil in the molecularly defined subtype CLL/SLL with IGHV somatic hypermutation were retrieved, resulting in an L5 evidence level for this prediction. Although extensive Phase 3 evidence exists for chlorambucil in CLL broadly — and the mechanistic rationale is sound — the IGHV-mutated subtype has not been independently validated as a distinct treatment target in this evidence pack.

To proceed, the following is needed:

Subgroup data extraction: Obtain IGHV-mutated subgroup analyses from existing Phase 3 chlorambucil-in-CLL trials (e.g., CLL11 obinutuzumab study, RESONATE-2 comparator arm) to determine whether the benefit–risk profile holds specifically for this molecular subset.
MOA data completion: Retrieve full DrugBank entry for chlorambucil (DB00291) to complete mechanistic link analysis and confirm pathway plausibility at the molecular level.
Safety documentation: Download the NPRA-approved Malaysian product monograph (仿單) to extract approved indication text, warnings, contraindications, and dosing recommendations; this is a blocking prerequisite for the S1 safety screening stage.
Regulatory review: Assess whether the IGHV-mutated CLL subtype would require a new indication filing or falls within the scope of the existing Malaysian approval; consult NPRA guidance on precision oncology label extensions.
Market intelligence: Clarify the current therapeutic landscape in Malaysia — whether BTK inhibitors (ibrutinib, acalabrutinib) or BCL-2 inhibitors (venetoclax) have displaced chlorambucil as standard of care, which would affect the repurposing value proposition.

This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any application to patient care.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.